Department of Clinical Sciences, Division of Pediatrics, Polytechnic University of Marche, Ospedali Riuniti, Presidio Salesi, Ancona, Italy.
Clinical Department of Pediatrics, ASST Santi Paolo e Carlo, San Paolo Hospital, University of Milan, Milan, Italy.
Mol Genet Metab. 2024 May;142(1):108444. doi: 10.1016/j.ymgme.2024.108444. Epub 2024 Mar 14.
Alpha-mannosidosis is an ultra-rare lysosomal disease that is caused by variants of the MAN2B1 gene on chromosome 19p13. These variants result in faulty or absent alpha-mannosidase in lysosomes, which leads to intracellular accumulation of mannose-containing oligosaccharides. Diagnosis of alpha-mannosidosis is often delayed, in part because of the rarity of the disease, its gradual onset and heterogeneity of presentation, but also because of the similarity of many signs and symptoms of the disease to those of other lysosomal diseases. Treatment of alpha-mannosidosis was previously limited to hematopoietic stem cell transplantation, but outcomes are variable and not all patients are eligible or have a suitable donor. Recently, an enzyme replacement therapy, recombinant human alpha-mannosidase (velmanase alfa), was approved for the treatment of non-neurological manifestations in adult and pediatric patients with alpha-mannosidosis. Treatment with velmanase alfa reduces serum levels of oligosaccharides, increases levels of immunoglobulin G, and improves patients' functional capacity and quality of life, although it is not effective for the neurologic phenotype because it does not cross the blood-brain barrier. Since the effects of velmanase alfa are more marked in children than adults, early diagnosis to allow early initiation of treatment has become more important. To support this, patient, parent/caregiver, and clinician awareness and education is imperative. A number of approaches can be taken to meet this goal, such as the development of disease registries, validated diagnostic algorithms, and screening tools, improved under-/post-graduate clinician education, easily accessible and reliable information for patients/families (such as that made available on the internet), and the formation of patient advocacy groups. Such approaches may raise awareness of alpha-mannosidosis, reduce the diagnostic delay and thus improve the lives of those affected.
α-甘露糖苷贮积症是一种超罕见的溶酶体疾病,由 19p13 染色体上 MAN2B1 基因的变异引起。这些变异导致溶酶体中缺乏或不存在α-甘露糖苷酶,导致含有甘露糖的寡糖在细胞内积累。α-甘露糖苷贮积症的诊断常常被延误,部分原因是该疾病罕见,其发病呈渐进性且表现具有异质性,还因为该疾病的许多体征和症状与其他溶酶体疾病相似。α-甘露糖苷贮积症的治疗以前仅限于造血干细胞移植,但治疗效果不一,并非所有患者都符合条件或有合适的供体。最近,一种酶替代疗法,重组人α-甘露糖苷酶(维拉曼酶),被批准用于治疗成人和儿科α-甘露糖苷贮积症患者的非神经表现。维拉曼酶治疗可降低血清寡糖水平,增加免疫球蛋白 G 水平,并改善患者的功能能力和生活质量,尽管它对神经表型无效,因为它不能穿过血脑屏障。由于维拉曼酶在儿童中的效果比成人更明显,因此尽早诊断以尽早开始治疗变得更加重要。为此,需要提高患者、家长/照顾者和临床医生的认识和教育。可以采取多种方法来实现这一目标,例如开发疾病登记处、验证诊断算法和筛查工具、改善医学生和住院医师的教育、为患者/家庭提供易于获取和可靠的信息(例如通过互联网提供的信息),以及成立患者倡导团体。这些方法可能会提高对α-甘露糖苷贮积症的认识,减少诊断延误,从而改善受影响者的生活。